MatthewKyleLabriolaMD

PubMed

• Patient engagement in designing and publishing research in prostate cancer: a scoping review.
  Thomas Bognanno, Shelby Moneer, Jennifer Ghith, Gustavo Rodriguez, Latorya Moore, Obaro Evuarherhe, Linda Sutton, Matthew Labriola, Alicia K Morgans> ;Future Oncology. 2024 Apr 4
• Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
  Jang, A., Barata, P. M., Joseph J Park, Alec Chu, Jinju Li, Alicia Ali, Rana R McKay, Clara Hwang, Matthew K Labriola, Albert Jang, Deepak Kilari, George Mo, Deepak Ra...> ;JCO Precision Oncology. 2024 Apr 1
• Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
  Park, J., Barata, P. M., Zeynep B Zengin, Nicholas C Henderson, Joseph J Park, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Laura Graham, G...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 22
• 2 citations
  Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
  Park, J., Holland, B., Jang, A., Barata, P. M., Clara Hwang, Nicholas C Henderson, Shih-Chun Chu, Brandon Holland, Frank C Cackowski, Amanda Pilling, Albert Jang, Shos...> ;JAMA Network Open. 2023 Sep 5
• Considerations for Designing and Implementing a Multi-institution Undergraduate Medical Education Experience.
  Steven King, Emma Y Wu, Christine Lin, Matthew Labriola, Myles Nickolich> ;Journal of Cancer Education. 2023 Oct 1
• Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer.
  Amanda Broderick, Matthew K Labriola, Neal Shore, Andrew J Armstrong> ;BMJ Case Reports. 2023 Jan 30
• 7 citations
  Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
  Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, Matthew K Labriola, Jennifer Tran, Konstantin H Dragnev, Laura J Tafe,...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
• How we manage grief.
  Anthony N Galanos, Matthew K Labriola> ;Clinical Advances in Hematology & Oncology. 2022 Sep 1
• Setting a new standard for long-term survival in metastatic kidney cancer.
  Matthew K Labriola, Daniel J George> ;Cancer. 2022 Jun 1
• Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observati...
  Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, ...> ;JMIR Cancer. 2022 May 19
• 16 citations
  PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
  Vadim S. Koshkin, Vaibhav G. Patel, Alicia Ali, Mehmet Asim Bilen, Deepak Ravindranathan, Joseph J. Park, Olesia Kellezi, Marcin Cieslik, Justin Shaya, Angelo Cabal, L...> ;Prostate Cancer and Prostatic Diseases. 2021 Aug 6
• 3 citations
  Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations.
  Matthew Labriola, Daniel J. George> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2021 Apr 30
• 55 citations
  LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
  Landon Carter Brown, Matthew D Tucker, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, T...> ;Journal for Immunotherapy of Cancer. 2021 Mar 1
• 21 citations
  Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
  Matthew Labriola, Saad O Atiq, Nathan Hirshman, Rhonda L. Bitting> ;Prostate Cancer and Prostatic Diseases. 2021 Jun 1
• 8 citations
  Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
  Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andre...> ;Oncoimmunology. 2020 Jun 10
• 1 citations
  PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
  Landon C. Brown, Jason Zhu, Matthew Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Z. Su, Shannon J. McCall, Jiaoti Huang, Wen-Chi Foo, Rajan T. Gupta,...> ;Clinical Genitourinary Cancer. 2020 Apr 10
• 58 citations
  Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
  Matthew Labriola, Jason Zhu, Rajan T. Gupta, Shannon J. McCall, Jennifer Jackson, Eric Kong, James R. White, Gustavo C. Cerqueira, Kelly Gerding, John K. Simmons, Dani...> ;Journal for Immunotherapy of Cancer. 2020 Mar 1
• 29 citations
  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
  Matthew Labriola, Kristen A. Batich, Jason Zhu, Megan Ann McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Tian Zhang> ;Clinical Genitourinary Cancer. 2019 Feb 5
• 60 citations
  Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2019 Feb 1
• 64 citations
  Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
  Jeffrey M. Conroy, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Le...> ;Journal for Immunotherapy of Cancer. 2019 Jan 24
• 1 citations
  Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.
  Matthew Labriola, Wen-Chi Foo, Daniel J. George, Tian Zhang> ;Clinical Genitourinary Cancer. 2018 Feb 23
• 4 citations
  Consent for organ donation after circulatory death at U.S. transplant centers.
  George E. Hardart, Matthew Labriola, Kenneth Prager, Marilyn C. Morris> ;AJOB Empirical Bioethics. 2017 Aug 2
• Join now to see all

Lectures

• Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic re... 
  2019 ASCO Annual Meeting - 6/1/2019